J. D. de Bono

Oncology · 2008–2021

A researcher in the Science corpus: 19 papers; trusts 4 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom J. D. de Bono trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Yves Pommier
  2. Mark J. O'Connor

Who trusts J. D. de Bono overall

  1. M. Miller
  2. M. Hallek
  3. G. Doyle
  4. Guocan Wang

Papers from J. D. de Bono's perspective

Ordered by how strongly the researchers J. D. de Bono trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase (Nature)
  2. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. (The Lancet Oncology)
  3. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (Proceedings of the National Academy of Sciences of the United States of America)
  4. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer (New England Journal of Medicine)
  5. Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse (EMBO Journal)
  6. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks (Cell)
  7. DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs (Chemistry and Biology)
  8. DNA repair dysregulation from cancer driver to therapeutic target (Nature Reviews. Cancer)
  9. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (EMBO Molecular Medicine)
  10. Repair Pathway Choices and Consequences at the Double-Strand Break (Trends in Cell Biology)

Their papers